List of Qdolo drug patents

Qdolo is owned by Athena.

Qdolo contains Tramadol Hydrochloride.

Qdolo has a total of 1 drug patent out of which 0 drug patents have expired.

Qdolo was authorised for market use on 01 September, 2020.

Qdolo is available in solution;oral dosage forms.

Qdolo can be used as management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

The generics of Qdolo are possible to be released after 01 September, 2040.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103452 ATHENA Tramadol hydrochloride solution
Sep, 2040

(17 years from now)

Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Dosage: SOLUTION;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic